Complexities in the pharmacologic management of osteoarthritis pain

References

• Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• Leigh JP, Seavey W, Leistikow B. Estimating the costs of job related arthritis. J Rheumatol 2001;28:1647-54
   PubMed Web of Science ®Google Scholar
• Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fab Physician 2012;85:49-56
   PubMed Web of Science ®Google Scholar
• Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49
   PubMed Web of Science ®Google Scholar
• Lubar D, White PH, Callahan LF, et al. A national public health agenda for osteoarthritis 2010. Semin Arthritis Rheum 2010;39:323-6
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Prognosis of osteoarthritis. Ann Rheum Dis 1996;55:685-8
   PubMed Web of Science ®Google Scholar
• Hadler NM. Knee pain is the malady – not osteoarthritis. Ann Intern Med 1992;116:598-9
   PubMed Web of Science ®Google Scholar
• Hinton R, Moody RL, Davis AW, Thomas SF. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002;65:841-8
   PubMed Web of Science ®Google Scholar
• Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60
   PubMed Web of Science ®Google Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41
   PubMed Web of Science ®Google Scholar
• Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003;28:2540-5
   PubMed Web of Science ®Google Scholar
• Rosemann T, Wensing M, Joest K, et al. Problems and needs for improving primary care of osteoarthritis patients: the views of patients, general practitioners and practice nurses. BMC Musculoskelet Disord 2006;7:48
   PubMed Web of Science ®Google Scholar
• Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635-46
   PubMed Web of Science ®Google Scholar
• Jordan JM, Helmick CG, Renner JB, et al. Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol 2007;34:172-80
   PubMed Web of Science ®Google Scholar
• Cisternas MG, Yelin E, Katz JN, et al. Ambulatory visit utilization in a national, population-based sample of adults with osteoarthritis. Arthritis Rheum 2009;61:1694-703
   PubMed Web of Science ®Google Scholar
• Hootman JM, Helmick CG, Schappert SM. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits, United States, 1997. Arthritis Rheum 2002;47:571-81
   PubMed Web of Science ®Google Scholar
• Jordan J, Luta G, Renner J, et al. Knee pain and knee osteoarthritis severity in self-reported task specific disability: the Johnston County Osteoarthritis Project. J Rheum 1997;24:1344-9
   PubMed Web of Science ®Google Scholar
• Creamer P, Hochberg MC. Why does osteoarthritis of the knee hurt – sometimes? Br J Rheumatol 1997;36:726-8
   PubMedGoogle Scholar
• Alford DP, Liebschutz J, Chen IA, et al. Update in pain medicine. J Gen Intern Med 2008;23:841-5
   PubMed Web of Science ®Google Scholar
• Carr DB, Goudas LC. Acute pain. Lancet 1999;353:2051-8
   PubMed Web of Science ®Google Scholar
• Nathan C. Points of control in inflammation. Nature 2002;420:846-52
   PubMed Web of Science ®Google Scholar
• Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Curr Med Res Opin 2011;27:1315-27
   PubMed Web of Science ®Google Scholar
• Creamer P, Hochberg MC. The relationship between psychosocial variables and pain reporting in osteoarthritis of the knee. Arthritis Care Res 1998;11:60-5
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Health Related Quality of Life Surveillance – United States. Morb Mortal Wkly Rep 2005;54(No. SS-4):22
   Google Scholar
• American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. American Geriatrics Society panel on the pharmacological management of persistent pain in older persons. Pain Med 2009;10:1062-83
   PubMed Web of Science ®Google Scholar
• Mann C, Gooberman-Hill R. Health care provision for osteoarthritis: concordance between what patients would like and what health professionals think they should have. Arthritis Care Res 2011;63:963-72
   Web of Science ®Google Scholar
• Gore M, Sadosky AB, Leslie DL, et al. Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain. Pain Pract 2012;12:457-68
   PubMed Web of Science ®Google Scholar
• Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Janagap C, et al. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med 2008;50:998-1005
   PubMed Web of Science ®Google Scholar
• Arellano FM, Yood MU, Wentworth CE, et al. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiol Drug Saf 2006;15:861-72
   PubMed Web of Science ®Google Scholar
• Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165:171-7
   PubMed Web of Science ®Google Scholar
• Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging 2007;24:441-51
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Fisher MC, Kremer J, et al. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol 2009;27:395-401
   PubMed Web of Science ®Google Scholar
• Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22
   PubMed Web of Science ®Google Scholar
• Shekelle PG, Ortiz E, Rhodes S, et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA 2001;286:1461-7
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Dickson J, Grant RL. Guideline development. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008;336:502-3
   PubMed Web of Science ®Google Scholar
• American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the Knee (non-arthroplasy). Rosemont, IL: American Academy of Orthopaedic Surgeons, 2008
   Google Scholar
• Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-62
   PubMed Web of Science ®Google Scholar
• Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 2010;18:476-99
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:455-74
   PubMed Web of Science ®Google Scholar
• Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005;165:1574-80
   PubMed Web of Science ®Google Scholar
• James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-506
   PubMed Web of Science ®Google Scholar
• Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 2006;15:398-405
   PubMed Web of Science ®Google Scholar
• Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010;376:190-201
   PubMed Web of Science ®Google Scholar
• Gyamlani GG, Parikh CR. Acetaminophen toxicity: suicidal vs. accidental. Crit Care 2002;6:155-9
   PubMed Web of Science ®Google Scholar
• Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. New Engl J Med 1997;337:1112-18
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA drug safety communication: prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm239821.htm [Last accessed 17 May 2012]
   Google Scholar
• Winn PA, Dentino AN. Effective pain management in the long-term care setting. J Am Med Dir Assoc 2004;5:342-52
   PubMedGoogle Scholar
• Healthcare MC. New initiative to help encourage appropriate use of acetaminophen. 2011. Available at: http://www.tylenol.com/page2.jhtml?id=tylenol/news/newdosing.inc [Last accessed 18 February 2013]
   Google Scholar
• Krenzelok EP, Royal MA. Confusion: acetaminophen dosing changes based on NO evidence in adults. Drugs in R&D 2012;12:45-8
   PubMedGoogle Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6
   PubMed Web of Science ®Google Scholar
• Rahme E, Barkun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008;103:872-82
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87
   PubMed Web of Science ®Google Scholar
• Forman JP, Rimm EB, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-9
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162:2204-8
   PubMed Web of Science ®Google Scholar
• Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002;40:604-8; discussion 601-3
   PubMed Web of Science ®Google Scholar
• Towheed TE, Maxwell L, Judd MG et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006(1):CD004257
   Google Scholar
• Hunt RH, Choquette D, Craig BN, et al. Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician 2007;53:1177-84
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public Health Advisory -- FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm [Last accessed 7 April 2005]
   Google Scholar
• Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010;170:1968-76
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9
   PubMed Web of Science ®Google Scholar
• Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004;11:17-25
   PubMedGoogle Scholar
• Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:iii-iv, 1-164
   PubMed Web of Science ®Google Scholar
• Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology 2010;49(Suppl 2):ii3-10
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005;365:475-81
   PubMed Web of Science ®Google Scholar
• Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case–control study. Stroke 2003;34:379-86
   PubMed Web of Science ®Google Scholar
• Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: a population-based, nested case–control analysis. Am J Epidemiol 2006;164:881-9
   PubMed Web of Science ®Google Scholar
• Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280:e281-7
   Web of Science ®Google Scholar
• Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110(Suppl 3A):33-42S
   PubMed Web of Science ®Google Scholar
• Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759-66
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen A-M, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction/clinical perspective. Circulation 2011;123:2226-35
   PubMed Web of Science ®Google Scholar
• Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32(3 Suppl 1):33-42
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case–control study from Finland. Eur Heart J 2006;27:1657-63
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm [Last accessed 5 March 2012]
   Google Scholar
• Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin Drug Investig 2012;32:221-33
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27:1243-53
   PubMed Web of Science ®Google Scholar
• Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379-86
   PubMed Web of Science ®Google Scholar
• Arnstein PM. Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients. Drugs Aging 2012;29:523-31
   PubMed Web of Science ®Google Scholar
• Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002-12
   PubMed Web of Science ®Google Scholar
• Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anesthetics update: EMLA and beyond. Dermatol Surg 2001;27:1019-26
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007;15:957-65
   Google Scholar
• Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010;37:1236-43
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers – United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-92
   PubMedGoogle Scholar
• Bollinger L. Under the Counter: The Diversion of Abuse of Controlled Prescription Drugs in the U.S. New York: Columbia University, 2005
   Google Scholar
• McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med 2011;123:119-30
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain 2005;6:662-72
   PubMed Web of Science ®Google Scholar
• Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7:43-8
   PubMed Web of Science ®Google Scholar
• Altman RD. Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care 2009;15(8 Suppl):S236-43
   PubMedGoogle Scholar
• Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil 2007;15:957-65
   PubMed Web of Science ®Google Scholar
• Scott WA. The relief of pain with an antidepressant in arthritis. Practitioner 1969;202:802-7
   PubMedGoogle Scholar
• Sullivan M, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain Med 2009;10:806-12
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA clears Cymbalta to treat chronic musculoskeletal pain. 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm232708.htm [Last accessed 23 July 2012]
   Google Scholar
• Hochberg MC, Wohlreich M, Gaynor P, et al. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol 2012;39:352-8
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. New Engl J Med 2005;352:1112-20
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Serotonin syndrome update. JAMA 2011;306:2661
   Web of Science ®Google Scholar
• Vuppalanchi R, Hayashi PH, Chalasani N, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010;32:1174-83
   PubMed Web of Science ®Google Scholar
• Kosuwon W, Sirichatiwapee W, Wisanuyotin T, et al. Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thai 2010;93:1188
   PubMedGoogle Scholar
• Chou R, McDonagh M, Nakamoto E, Griffin J. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. Rockville (MD): Agency for Healthcare Research and Quality (US), 2011
   Google Scholar
• Gammaitoni AR, Galer BS, Onawola R, et al. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the neuropathic pain scale. CMRO 2004;20(S2):13-19
   Google Scholar
• Kivitz A, Fairfax M, Sheldon EA, et al. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther 2008;30:2366
   PubMed Web of Science ®Google Scholar
• Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther 2001;26:257-64
   PubMed Web of Science ®Google Scholar
• Buescher JJ, Meadows S, Saseen J. Do acetaminophen and a NSAID combined relieve osteoarthritis pain better than either alone? J Fam Pract 2004;53:501-3
   PubMed Web of Science ®Google Scholar
• Ong CKS, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010;110:1170-9
   PubMed Web of Science ®Google Scholar
• Rosenthal NR, Silverfield JC, Wu S-C, et al, on behalf of the CAPSS-105 Study Group. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc 2004;52:374-80
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006(3):CD005522
   Google Scholar
• Park K-S, Choi J-J, Kim W-U, et al. The efficacy of tramadol/acetaminophen combination tablets (Ultracet®) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID). Clin Rheumatol 2012;31:317-23
   PubMed Web of Science ®Google Scholar
• Emkey R, Rosenthal N, Wu S-C, et al. CAPSS-114 Study Group. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004;31:150-6
   PubMed Web of Science ®Google Scholar
• Ultracet (tramadol hydrochloride/acetaminophen tablets) Full Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, 2011
   Google Scholar
• Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum 2008;59:1207-13
   PubMed Web of Science ®Google Scholar
• Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Investig 1997;15;99:1231-7
   Web of Science ®Google Scholar
• Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000;43:378-85
   PubMed Web of Science ®Google Scholar
• Dray A, Read S. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 2007;9:212
   PubMed Web of Science ®Google Scholar
• Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing 2012;41:646-52
   PubMed Web of Science ®Google Scholar
• McAlindon TE, Driban JB, Lo GH. Osteoarthritis year 2011 in review: clinical. Osteoarthr Cartil 2012;20:197-200
   PubMed Web of Science ®Google Scholar
• Nagashima H, Suzuki M, Araki S, et al. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthr Cartil 2011;19:1405-12
   PubMed Web of Science ®Google Scholar